Private Markets, Angel and Secondary Investing, Sacra

Sacra

Private Markets, Angel and Secondary Investing

Bringing transparency to private markets so investors, founders, and employees can build on conviction. Sacra delivers deeply researched insights on the private companies shaping tomorrow's markets. By surfacing the data, context, and operator perspective that are missing from private markets today, we help secondary buyers and sellers price equity accurately and unlock liquidity for the people building these businesses.

Private Capital Markets

AI coworker that executes business tasks inside Slack and Microsoft Teams

<ul><li>Sacra estimates that Viktor hit $50M in annualized revenue in September 2026.</li><li>Viktor raised a $75M Series A led by Accel in May 2026, with angel participation from Slack co-founders Stewart Butterfield and Cal Henderson and Vercel founder Guillermo Rauch.</li><li>In October 2026, Viktor listed more than 70,000 teams using its AI coworker across marketing, operations, finance, and engineering.</li></ul>

Sacra estimates that Viktor hit $50M in annualized revenue in September 2026.Viktor raised a $75M Series A led by Accel in May 2026, with angel participation from Slack co-founders Stewart Butterfield and Cal Henderson and Vercel founder Guillermo Rauch.In October 2026, Viktor listed more than 70,000 teams using its AI coworker across marketing, operations, finance, and engineering.

Chatbot-based personal finance tool for Gen Z offering credit coaching and cash advances

<ul><li>Sacra estimates Cleo reached $400M in annualized revenue in May 2026, up 20% from the $333M run rate it reported at the end of 2025 and more than double its $186M run rate at the end of 2024.</li><li>Cleo generated $254.1M in revenue in 2025, up 87% from $135.7M in 2024 and $65.9M in 2023.</li><li>Cleo reported an $18.6M operating loss and a $39.4M net loss in 2025.</li></ul>

Sacra estimates Cleo reached $400M in annualized revenue in May 2026, up 20% from the $333M run rate it reported at the end of 2025 and more than double its $186M run rate at the end of 2024.Cleo generated $254.1M in revenue in 2025, up 87% from $135.7M in 2024 and $65.9M in 2023.Cleo reported an $18.6M operating loss and a $39.4M net loss in 2025.

E-commerce flower delivery service with personalized ordering and letterbox packaging

<ul><li>Bloom &amp; Wild generated £116.57M in consolidated revenue (approximately $149M) in its fiscal year ended March 31, 2025.</li><li>In fiscal 2024, the business turned profitable with $5.6M in adjusted EBITDA, an improvement of $12M year-over-year, driven by tighter cost controls and reduced marketing spend.</li><li>Over the next several years, ecommerce’s share of the flower delivery market is expected to continue to grow, mainly at the expense of local florists.</li></ul>

Bloom &amp; Wild generated £116.57M in consolidated revenue (approximately $149M) in its fiscal year ended March 31, 2025.In fiscal 2024, the business turned profitable with $5.6M in adjusted EBITDA, an improvement of $12M year-over-year, driven by tighter cost controls and reduced marketing spend.Over the next several years, ecommerce’s share of the flower delivery market is expected to continue to grow, mainly at the expense of local florists.

Payment processing software for enterprises to accept, manage, and disburse global transactions

<ul><li>Checkout.com reported $750M in annualized net revenue in September 2026, alongside 28% YoY growth on a trailing-twelve-month basis.</li><li>Checkout.com processed more than $300B in payments in 2025, up 64% YoY, and returned to full-year EBITDA profitability with an adjusted EBITDA margin above 10%.</li><li>Checkout.com reported US processing volume growth above 120% year to date in September 2026, with the US accounting for 20% of group payment volume, up from 15% a year earlier.</li></ul>

Checkout.com reported $750M in annualized net revenue in September 2026, alongside 28% YoY growth on a trailing-twelve-month basis.Checkout.com processed more than $300B in payments in 2025, up 64% YoY, and returned to full-year EBITDA profitability with an adjusted EBITDA margin above 10%.Checkout.com reported US processing volume growth above 120% year to date in September 2026, with the US accounting for 20% of group payment volume, up from 15% a year earlier.

Isomorphic Labs / Private Capital Markets

AI-first drug discovery platform that applies protein-structure prediction and generative models to design therapeutic candidates

<ul><li>Isomorphic Labs raised a $2.1B Series B in May 2026 led by Thrive Capital, with participation from Alphabet, GV, MGX, Temasek, CapitalG, and the UK Sovereign AI Fund.</li><li>Isomorphic says this process can compress months of physical iteration into two to four days of computational design, followed by targeted laboratory validation.</li><li>The $2.1B Series B, appointment of a chief medical officer, and establishment of a Cambridge, Massachusetts presence indicate this shift.</li></ul>

Isomorphic Labs raised a $2.1B Series B in May 2026 led by Thrive Capital, with participation from Alphabet, GV, MGX, Temasek, CapitalG, and the UK Sovereign AI Fund.Isomorphic says this process can compress months of physical iteration into two to four days of computational design, followed by targeted laboratory validation.The $2.1B Series B, appointment of a chief medical officer, and establishment of a Cambridge, Massachusetts presence indicate this shift.

Europe ECM
Coverage of European IPOs & Placements

Primer: Viktor - 12 Oct 2026

AI coworker that executes business tasks inside Slack and Microsoft Teams

Sacra

Primer: Cleo - 12 Oct 2026

Chatbot-based personal finance tool for Gen Z offering credit coaching and cash advances

Sacra

Primer: Bloom & Wild - 12 Oct 2026

E-commerce flower delivery service with personalized ordering and letterbox packaging

Sacra

Primer: Checkout.com - 12 Oct 2026

Payment processing software for enterprises to accept, manage, and disburse global transactions

Sacra

Primer: Isomorphic Labs - 30 Sep 2026

AI-first drug discovery platform that applies protein-structure prediction and generative models to design therapeutic candidates

Sacra